The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly shares an update on the QuANTUM-First (NCT02668653) trial evaluating quizartinib plus chemotherapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML), highlighting that the analysis of mutation subsets is being refined and data on the mutational profile for relapsed patients is forthcoming. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Only that we are refining our analysis of the mutation subsets that benefited most and the so-called triple mutation of DNMT3A, NPM1, FLT3ITD denotes a particular subset of AML that is exquisitely sensitive to FLT3 inhibition. And then we are preparing data on the mutational profile for relapsed patients, which is interesting, how many patients lost the FLT3 mutation, et cetera. So those data are coming soon...
Only that we are refining our analysis of the mutation subsets that benefited most and the so-called triple mutation of DNMT3A, NPM1, FLT3ITD denotes a particular subset of AML that is exquisitely sensitive to FLT3 inhibition. And then we are preparing data on the mutational profile for relapsed patients, which is interesting, how many patients lost the FLT3 mutation, et cetera. So those data are coming soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
